Recreational abuse of newly emerging """"""""club drugs"""""""" including atypical hallucinogens is a significant and growing national problem. Abuse of these drugs among adolescents, often exacerbated by internet websites, is a particular concern. Research in this project will focus on four such compounds for which there are major gaps in our understanding of the comparative human clinical pharmacology: GHB (gamma- hydroxybutyric acid), ketamine, dextromethorphan, and salvinorin A. For all four compounds, double-blind dose-effect studies will be conducted in subjects with histories of drug abuse and drug effects will be assessed using various subjective, behavioral, psychomotor performance, cognitive, memory and/or physiological measures. More specifically, Experiments 1 and 2 will extend previous studies of GHB, a novel abused sedative, to provide new information about the reinforcing and behavioral/cognitive effects of GHB as usually abused by studying the repeated self-administration of low doses of GHB over 3-hour self- administration sessions, and by comparing the effects of GHB to ethanol, the world's most commonly abused sedative drug. Experiments 3-5 will advance understanding of the abuse liability and high dose effects of three compounds abused for their dissociative and hallucinogenic effects. In all three experiments, a dose run-up pilot study will precede the subsequent randomized cross-over comparative pharmacology study comparing placebo and three doses each of the compound of interest relative to a comparison standard. More specifically, Experiment 3 will characterize the effects of ketamine, a classic NMDA (N- methyl-D-aspartic acid) antagonist, by evaluating a range of intramuscularly administered doses of ketamine relative to intramuscularly administered midazolam as the comparison standard. Experiment 4 will examine a range of orally administered doses of the dextromethorphan, a widely available novel NMDA antagonist, relative to oral doses of ketamine as the comparison standard. Finally Experiment 5 will use a similar approach to characterize the effects of salvinorin A, a novel selective kappa opioid agonist that is becoming a significant hallucinogen of abuse. These studies will provide new information about the abuse potential and toxic effects of four recreationally abused drugs of national concern. Because the drugs proposed for study have unique and selective cellular sites of action (i.e. GHB/GABAB, NMDA, and kappa opioid receptors), this research also may provide new insights about basic pharmacological mechanisms of action, with relevance for developing new therapies for a variety of disorders including drug dependence. Ultimately, this comparative pharmacology research program should have relevance to the development of drug abuse prevention and treatment strategies for these emerging drugs of abuse.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA003889-27
Application #
7845691
Study Section
Biobehavioral Regulation, Learning and Ethology Study Section (BRLE)
Program Officer
Schnur, Paul
Project Start
1984-07-01
Project End
2012-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
27
Fiscal Year
2010
Total Cost
$445,391
Indirect Cost
Name
Johns Hopkins University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Johnson, Matthew W; Garcia-Romeu, Albert; Johnson, Patrick S et al. (2017) An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. J Psychopharmacol 31:841-850
Johnson, Matthew W; Griffiths, Roland R (2017) Potential Therapeutic Effects of Psilocybin. Neurotherapeutics 14:734-740
Barrett, Frederick S; Johnson, Matthew W; Griffiths, Roland R (2017) Neuroticism is associated with challenging experiences with psilocybin mushrooms. Pers Individ Dif 117:155-160
Johnson, Matthew W; Garcia-Romeu, Albert; Griffiths, Roland R (2017) Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse 43:55-60
Carbonaro, Theresa M; Bradstreet, Matthew P; Barrett, Frederick S et al. (2016) Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. J Psychopharmacol 30:1268-1278
Griffiths, Roland R; Johnson, Matthew W; Carducci, Michael A et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 30:1181-1197
Barrett, Frederick S; Bradstreet, Matthew P; Leoutsakos, Jeannie-Marie S et al. (2016) The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol 30:1279-1295
Johnson, Matthew W; MacLean, Katherine A; Caspers, Michael J et al. (2016) Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans. J Psychopharmacol 30:323-9
Maqueda, Ana Elda; Valle, Marta; Addy, Peter H et al. (2016) Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans. Int J Neuropsychopharmacol 19:
Maqueda, Ana Elda; Valle, Marta; Addy, Peter H et al. (2015) Salvinorin-A Induces Intense Dissociative Effects, Blocking External Sensory Perception and Modulating Interoception and Sense of Body Ownership in Humans. Int J Neuropsychopharmacol 18:

Showing the most recent 10 out of 103 publications